ADVM—While dose de-escalation is pretty common in a phase-1 trial (e.g. the standard "3x3" design), what we have with ADVM is unplanned de-escalation following a clinical hold. That's an altogether different story that warrants the skepticism shown in the tweets you cited.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.